Here we go again: An op-ed column printed in this publication is yet another example of a drug company-focused view on the 340B Drug Pricing Program, couched in the language of reform. Its criticisms ...

Despite the rancor, there are many bipartisan opportunities for the divided 118 th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug ...

Providers and drugmakers are once again at odds over the 340B drug discount program: this time, over a rule finalized by the Biden administration on Thursday making changes to its dispute resolution ...

The 340B drug discount program incentivizes hospitals to purchase outpatient clinics and prescribe more and higher-cost drugs — behaviors that tend to increase costs for the federal government and ...

On February 2, 2024, the “gang of six”—a bipartisan group of six senators who have traditionally championed reforms to the 340B program 1 —introduced a discussion draft of a bill that would modify the ...

The 340B Drug Pricing Program was created in 1992 and allows hospitals and clinics that treat a large population of low-income and uninsured patients to buy outpatient prescription drugs at a discount ...

This past September, a sub-agency of the Department of Health and Human Services (HHS) threatened to kick a pharmaceutical company out of Medicare because the company, in line with federal law, ...

The 340B Drug Pricing Program is a federal lifeline for vulnerable and underserved communities across the U.S., and its importance in Orlando is profound. Created to allow health-care safety-net ...

Drug companies are at it again. They will not relent in their multiyear campaign to dismantle the 340B Drug Pricing Program. Drug companies are at it again. They will not relent in their multiyear ...